Amicus therapeutics, inc. (FOLD)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Mar'12
Operating activities
Net loss

-325,037

-356,388

-344,740

-442,094

-419,378

-348,995

-340,122

-292,624

-278,926

-284,002

-273,441

-208,430

-211,343

-200,042

-184,291

-175,438

-151,521

-132,118

-110,442

-89,790

-77,271

-68,926

0

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and deferred financing

1,128

2,546

5,398

7,807

10,024

10,976

10,392

10,261

9,901

9,703

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

5,548

4,775

4,462

4,419

4,238

4,216

4,122

3,899

3,739

3,593

3,392

3,438

3,392

3,242

2,913

2,412

1,998

1,833

1,620

1,600

1,643

1,547

0

0

0

0

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,370

860

492

237

298

301

277

0

0

0

-

Amortization of non-cash compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Stock-based compensation

44,282

44,430

39,909

38,120

34,526

29,260

26,907

25,353

24,549

23,101

21,484

20,323

19,251

17,504

16,130

14,529

12,295

9,972

8,539

7,451

6,708

6,008

0

0

0

0

Loss on exchange of convertible debt

-4,500

-40,600

-40,600

-40,624

-36,100

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restructuring charges

-

-

-

-

-

-

-

-

-

-

-

-

-

69

40

37

55

15

55

62

-45

-63

0

0

0

-

Change in fair value of derivatives

-

-

-

-

-

-2,739

-2,739

-2,739

4,963

265

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash changes in the fair value of contingent consideration payable

2,845

3,297

3,252

3,763

3,583

3,300

7,000

-238,550

-237,800

-234,322

-241,090

-950

8,186

6,760

11,205

16,615

6,529

4,377

0

0

0

-

-

0

0

-

Foreign currency remeasurement loss

-10,591

-254

-5,107

-1,640

-6,499

-3,217

-87

510

7,973

5,620

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash deferred taxes

-

-

-

-

-

-

-

-

-

167,305

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

(Gain) loss on disposal of assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Stock-based compensation - non-employees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Stock-based license payments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Beneficial conversion feature related to bridge financing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Changes in operating assets and liabilities:
Accounts receivable

18,471

11,114

20,756

14,080

13,248

13,294

8,619

11,542

8,260

7,725

0

0

0

-

-

-

-

-

-

-

-

-1,083

0

0

0

0

Inventories

5,710

5,114

4,172

2,664

607

4,205

-440

3,995

3,907

897

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

2,330

3,287

3,466

5,619

5,328

-2,488

9,338

8,642

-1,392

15,329

949

1,632

6,146

394

1,827

1,198

204

-308

1,808

1,311

1,182

-2,293

0

0

0

0

Other non-current assets

-

-

-

-

-

-

-

-

-

-

-34

936

1,051

970

786

733

646

666

0

0

0

-

-

-

-

0

Accounts payable and accrued expenses

20,349

46,742

22,145

41,369

18,604

17,115

3,210

5,059

3,487

12,563

23,088

11,078

15,623

7,131

-1,571

6,764

6,255

15,467

19,074

6,783

6,605

6,169

0

0

0

0

Other non-current assets and liabilities

-11,944

-10,117

1,803

-1,064

-3,925

-581

-1,066

-841

-535

-9

778

786

808

825

810

712

191

93

0

0

0

-

-

-

-

-

Deferred reimbursements

-4,000

-5,500

-2,750

-2,750

-7,750

-6,250

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash used in operating activities

-279,812

-250,416

-253,261

-330,470

-328,980

-299,955

-312,312

-228,454

-213,373

-213,695

-172,259

-164,233

-155,054

-150,147

-154,060

-134,199

-124,100

-100,139

-79,136

-73,241

-62,424

-51,669

0

0

0

0

Investing activities
Sale and redemption of marketable securities

470,000

499,047

464,609

514,688

477,463

463,502

480,907

396,083

375,536

323,753

286,860

238,000

237,660

221,374

322,206

348,249

302,547

290,129

141,373

87,963

85,188

55,914

0

0

0

0

Purchases of marketable securities

343,792

383,882

449,396

389,478

327,562

578,394

481,073

686,208

632,355

490,468

470,461

277,512

330,334

219,932

268,563

386,095

321,995

289,595

308,504

164,317

163,846

162,752

0

0

0

0

Capital expenditures

17,874

20,012

10,824

9,537

8,433

6,308

5,699

4,128

4,613

4,526

3,829

3,622

3,805

5,951

8,091

7,996

6,942

4,817

2,292

1,535

951

238

0

0

0

0

Net cash provided by investing activities

108,334

95,153

4,389

115,673

141,468

-121,200

-5,865

-294,253

-261,432

-171,241

-187,430

-43,134

-96,479

-4,509

45,552

-186,902

-167,450

-145,343

-310,483

-77,889

-79,609

-107,076

0

0

0

0

Financing activities
Proceeds from the issuance of preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from Issuance of Common Stock

-

-

-

-

-

294,584

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Payment of finance leases

366

420

293

290

338

334

314

308

308

308

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments of secured loan agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

299

0

0

0

0

Purchase of vested restricted stock units

8,840

3,235

3,152

3,360

2,858

2,832

3,210

2,620

3,247

1,596

1,339

1,628

886

1,282

0

0

0

-

-

-

-

-

-

-

-

-

Proceeds from termination of capped call confirmations

-34,475

-19,875

19,875

19,900

14,600

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

13,600

11,476

8,460

8,324

9,119

9,144

15,952

22,327

20,014

16,301

10,421

3,943

3,146

3,036

1,969

4,901

7,278

11,186

12,249

10,580

7,721

3,673

0

0

0

0

Payment of deferred financing fees

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds of exercise of warrants

0

812

812

812

4,429

3,617

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Capital expenditures funded by capital lease

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of contingent consideration

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible notes, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from exercise of warrants (common and preferred)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from capital asset financing arrangement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from loan agreements, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash (used in) provided by financing activities

198,631

217,502

214,670

360,951

171,580

450,775

457,280

560,665

544,108

247,434

390,889

180,335

273,122

272,715

122,547

136,414

286,328

290,893

389,387

358,249

143,327

139,179

0

0

0

0

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

-186

1,729

73

1,593

-1,692

1,518

-850

-304

2,106

1,326

1,262

1,163

44

-131

0

0

0

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents, and restricted cash at the end of the period

26,967

63,968

-34,129

147,747

-17,624

31,138

138,253

37,654

71,409

-136,176

32,462

-25,869

21,633

117,928

13,676

-185,367

-5,317

45,411

-232

207,119

1,294

-19,566

0

0

0

0

Supplemental disclosures of cash flow information
Tenant improvements paid through lease incentives

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid during the period for interest

15,813

16,966

16,858

13,028

12,334

7,500

7,549

7,548

7,424

7,424

0

0

0

-

-

-

-

605

927

1,254

1,187

1,186

0

0

0

0

Contingent consideration paid in shares

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Capital expenditures unpaid at the end of period

2,454

1,865

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash activities
Conversion of notes payable to Series B redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Conversion of preferred stock to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Beneficial conversion feature related to the issuance of Series C redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0